2 型糖尿病管理的新型治疗方法：第 2 部分。2013 年在临床环境中解决肠促胰岛素缺陷。

Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.

机构信息

Grunberger Diabetes Institute, Bloomfield Hills, Michigan 48302, USA.

出版信息

J Diabetes. 2013 Sep;5(3):241-53. doi: 10.1111/1753-0407.12046. Epub 2013 May 29.

DOI:10.1111/1753-0407.12046

Abstract

The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called "incretin defect" in patients with T2DM.

摘要

本文简要综述并更新了过去 8 年中用于 2 型糖尿病治疗的两类药物的临床经验：（i）胰高血糖素样肽-1 受体激动剂；（ii）二肽基肽酶 4 抑制剂。这两类药物均针对 2 型糖尿病患者所谓的“肠促胰岛素缺陷”。